We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Nymox Pharmaceutical Corp | NASDAQ:NYMX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.20 | 0.2003 | 0.2169 | 0 | 01:00:00 |
Nymox CEO Paul Averback said, "These funds bolster Nymox's balance sheet and together with budgetary adjustments will allow the Company to more securely continue development activities for our Phase 3 BPH NX-1207 program and our Phase 2 NX-1207 prostate cancer program."
The Company's NASDAQ Capital Market requirements are currently deficient and it has a 6 month period in which to regain compliance. Market value must be a minimum of $35 million and share price $1 for a minimum of 10 consecutive days to regain compliance.
Jack Gemmell and Dr. Roger Guy have resigned from the Board of Directors. The Company gratefully acknowledges their service.
For more information please contact info@nymox.com or 800-936-9669.
This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Development of drug products involves substantial risks and actual results may differ materially from expectations. Factors that could cause actual results or events to differ materially from those projected in forward-looking statements are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.
CONTACT: For Further Information Contact: Paul Averback Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com
1 Year Nymox Pharmaceutical Chart |
1 Month Nymox Pharmaceutical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions